eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
6/2012
vol. 16
 
Share:
Share:
abstract:
Review paper

Lipoprotein lipase; a new prognostic factor in chronic lymphocytic leukemia

Mariusz L. Hartman
,
Zofia M. Kilianska

Wspolczesna Onkol 2012; 16 (5): 474–479
Online publish date: 2013/01/04
View full text Get citation
 
PlumX metrics:
The clinical course of patients with chronic lymphocytic leukemia (CLL) is highly heterogeneous. Gene expression analyses have revealed that leukemic cells with unmutated immunoglobulin heavy chain genes (IgVH) differ from CLL cells with mutated IgVH in the expression level of some genes, i.e. encoding kinase ZAP-70 and antigen CD38. Recently, additional markers in CLL, including the expression level of apoptosis-regulating genes/proteins (Bcl-2, Mcl-1) and microRNAs, have been suggested. In this review, we attempt to provide data concerning the properties of lipoprotein lipase (LPL), as well as to present its prognostic value in CLL. LPL mRNA expression level was able to predict mutational status in a high percentage of CLL cases and high LPL expression was associated with shorter treatment-free survival. Importantly, since LPL activity is low (or absent) in other blood cell types, its expression can be determined by PCR technique in peripheral blood mononuclear cells or in lysed blood samples.
keywords:

chronic lymphocytic leukemia, prognostic factors, lipoprotein lipase, IgVH mutational status

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.